| 2024-09-17 |
复牌提示：
2024-09-16 19:50:00 停牌，复牌日期 2024-09-18 00:00:01
|
| 2024-08-19 |
详情>>
内部人交易：
Klemz Kevin M股份减少2268.00股
|
| 2024-08-07 |
详情>>
股本变动：
变动后总股本4063.21万股
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-0.78美元,归母净利润-3073.9万美元,同比去年增长-2.65%
|
| 2024-07-29 |
股东大会：
将于2024-09-05召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated June 17, 2024 (which we refer to, as it may be amended, modified, supplemented or waived from time to time, as the “merger agreement”), by and among Silk Road, Boston Scientific Corporation, a Delaware corporation (which we refer to as “Boston Scientific”) and Seminole Merger Sub, Inc., a Delaware corporation (which we refer to as “Merger Sub”);
2.To consider and vote on a proposal to approve, on a non-binding, advisory basis, the compensation that will or may become payable by Silk Road to our named executive officers in connection with the merger of Merger Sub with and into Silk Road (which we refer to as the “merger”);
3.To consider and vote on a proposal to adjourn the special meeting, from time to time, to a later date or dates, if necessary or appropriate, including to solicit additional proxies if there are insufficient votes to adopt the merger agreement at the time of the special meeting.
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.36美元,归母净利润-1413.6万美元,同比去年增长14.12%
|
| 2024-04-30 |
财报披露：
美东时间 2024-04-30 盘后发布财报
|
| 2024-04-26 |
股东大会：
将于2024-06-18召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to serve as members of the board of directors of Silk Road Medical until the next annual meeting of stockholders and until their successors are duly elected and qualified. The director nominees named in the proxy statement for election to the board of directors are: Jack W. Lasersohn, Chas S. McKhann, Rick D. Anderson, Kevin J. Ballinger, Tanisha V. Carino, Ph.D., Tony M. Chou, M.D., Elizabeth H. Weatherman and Donald J. Zurbay;
2.To approve, on an advisory basis, our executive compensation;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024;
4.To transact such other business as may properly come before the Annual Meeting or at any continuation, postponement, or adjournment thereof.
|
| 2024-02-28 |
详情>>
业绩披露：
2021年年报每股收益-1.44美元,归母净利润-4981.1万美元,同比去年增长-5.16%
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-1.44美元,归母净利润-5574.3万美元,同比去年增长-1.33%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.1美元,归母净利润-4273.2万美元,同比去年增长-0.79%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.77美元,归母净利润-2994.4万美元,同比去年增长6.65%
|
| 2023-05-09 |
详情>>
业绩披露：
2022年一季报每股收益-0.48美元,归母净利润-1667.9万美元,同比去年增长-55.97%
|
| 2023-05-09 |
详情>>
业绩披露：
2023年一季报每股收益-0.43美元,归母净利润-1646万美元,同比去年增长1.31%
|
| 2023-04-28 |
股东大会：
将于2023-06-21召开股东大会
会议内容 ▼▲
- 1.To elect three Class I and two Class III directors to serve until the 2024 annual meeting of stockholders;
2.To hold an advisory vote to approve Named Executive Officer Compensation;
3.To adopt and approve an amendment to our Certificate of Incorporation to eliminate or limit the personal liability of officers;
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023;
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2023-02-28 |
详情>>
业绩披露：
2022年年报每股收益-1.54美元,归母净利润-5501万美元,同比去年增长-10.44%
|
| 2022-11-09 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.21美元,归母净利润-4239.6万美元,同比去年增长-20.72%
|
| 2022-08-09 |
详情>>
业绩披露：
2022年中报每股收益-0.91美元,归母净利润-3207.7万美元,同比去年增长-51.07%
|
| 2022-04-29 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors to serve until the 2023 annual meeting of stockholders and until their successors are duly elected and qualified;
2.To hold an advisory vote to approve Named Executive Officer Compensation;
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022;
4.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-26 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to serve until the 2024 annual meeting of stockholders and until their successors are duly elected and qualified;
2.To adopt and approve amendments to our Certificate of Incorporation to phase out the classified structure of our Board of Directors;
3.To hold an advisory vote to approve Named Executive Officer Compensation;
4.To hold an advisory vote on the frequency of advisory votes on Named Executive Officer Compensation;
5.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021;
6.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2020-05-28 |
股东大会：
将于2020-07-08召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors to serve until the 2023 annual meeting of stockholders and until their successors are duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020;
3.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|